IL2 and cancer: In addition, we show that the treatment of TPR/IL2-expanded PBMCs with EpCAM-ReTARGTPRIFNαR149A in the absence of cancer cells promotes T-cell viability and persistence and increases the number of viable T cells from 4 × 105 up to 6 × 105 cells/mL compared to treatment with EpCAM-ReTARGTPR (Figure 4H).